RT Journal Article
SR Electronic
T1 International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 959
OP 960
DO 10.3899/jrheum.160114
VO 43
IS 5
A1 Joseph F. Merola
A1 April W. Armstrong
A1 Ami Saraiya
A1 John Latella
A1 Amit Garg
A1 Kristina Callis Duffin
A1 Alice B. Gottlieb
YR 2016
UL http://www.jrheum.org/content/43/5/959.abstract
AB Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.